Division of Diagnostic and Interventional Radiology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Insights Imaging. 2013 Aug;4(4):481-90. doi: 10.1007/s13244-013-0247-7. Epub 2013 May 15.
The purpose of this study was to evaluate if positron emission tomography (PET)/magnetic resonance imaging (MRI) with just one gradient echo sequence using the body coil is diagnostically sufficient compared with a standard, low-dose non-contrast-enhanced PET/computed tomography (CT) concerning overall diagnostic accuracy, lesion detectability, size and conspicuity evaluation.
Sixty-three patients (mean age 58 years, range 19-86 years; 23 women, 40 men) referred for either staging or restaging/follow-up of various malignant tumours (malignant melanoma, lung cancer, breast cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, CUP, gynaecology tumours, pleural mesothelioma, oesophageal cancer, colorectal cancer, stomach cancer) were prospectively included. Imaging was conducted using a tri-modality PET/CT-MR set-up (full ring, time-of-flight Discovery PET/CT 690, 3 T Discovery MR 750, both GE Healthcare, Waukesha, WI). All patients were positioned on a dedicated PET/CT- and MR-compatible examination table, allowing for patient transport from the MR system to the PET/CT without patient movement. In accordance with RECIST 1.1 criteria, measurements of the maximum lesion diameters on CT and MR images were obtained. In lymph nodes, the short axis was measured. A four-point scale was used for assessment of lesion conspicuity: 1 (>25 % of lesion borders definable), 2 (25-50 %), 3 (50-75 %) and 4 (>75 %). For each lesion the corresponding anatomical structure was noted based on anatomical information of the spatially co-registered PET/CT and PET/MRI image sections. Additionally, lesions were divided into three categories: "tumour mass", "lymph nodes" and "lesions". Differences in overall lesion detectability and conspicuity in PET/CT and PET/MRI, as well as differences in detectability based on the localisation and lesion type, were analysed by Wilcoxon signed rank test.
A total of 126 PET-positive lesions were evaluated. Overall, no statistically significant superiority of PET/CT over PET/MRI or vice versa in terms of lesion conspicuity was found (p = 0.095; mean score CT 2.93, mean score MRI 2.75). A statistically significant superiority concerning conspicuity of PET/CT over PET/MRI was found in pulmonary lesions (p = 0.016). Additionally, a statistically significant superiority of PET/CT over PET/MRI in "lymph nodes" regarding lesion conspicuity was also found (p = 0.033). A higher mean score concerning bone lesions were found for PET/CT compared with PET/MRI; however, these differences did not achieve statistical significance.
Overall, PET/MRI with body coil acquisition does not match entirely the diagnostic accuracy of standard low-dose PET/CT. Thus, it might only serve as a back-up solution in very few patients. Overall, more time needs to be invested on the MR imaging part (higher matrix, more breath-holds, additional surface coil acquired sequences) to match up with the standard low-dose PET/CT.
• Evaluation of whether PET/MRI with one sequence using body coil is diagnostically sufficient compared with PET/CT • PET/MRI with body coil does not match entirely the diagnostic accuracy of standard low-dose PET/CT • PET/MRI might only serve as a backup solution in patients.
本研究旨在评估使用体线圈进行单次梯度回波序列的正电子发射断层扫描(PET)/磁共振成像(MRI)与标准低剂量非对比增强 PET/计算机断层扫描(CT)相比,在整体诊断准确性、病变检出率、大小和显著性评估方面是否具有诊断意义。
63 名患者(平均年龄 58 岁,范围 19-86 岁;23 名女性,40 名男性)因各种恶性肿瘤(恶性黑色素瘤、肺癌、乳腺癌、霍奇金淋巴瘤、非霍奇金淋巴瘤、CUP、妇科肿瘤、胸膜间皮瘤、食管癌、结直肠癌、胃癌)的分期或随访而被前瞻性纳入研究。使用三模态 PET/CT-MR 设备(全环、飞行时间 Discovery PET/CT 690、3T Discovery MR 750,均为通用电气医疗,威斯康星州沃基肖)进行成像。所有患者均置于专用的 PET/CT 和 MR 兼容检查台上,允许患者在不移动的情况下从 MR 系统转移到 PET/CT。根据 RECIST 1.1 标准,在 CT 和 MR 图像上获得最大病变直径的测量值。在淋巴结中,测量短轴。病变显著性评估采用 4 分制:1(>25%的病变边界可定义)、2(25-50%)、3(50-75%)和 4(>75%)。对于每个病变,根据空间配准的 PET/CT 和 PET/MRI 图像部分的解剖学信息,记录相应的解剖结构。此外,病变分为三类:“肿瘤肿块”、“淋巴结”和“病变”。分析了 PET/CT 和 PET/MRI 中整体病变检出率和显著性差异,以及基于病变位置和类型的检出率差异,采用 Wilcoxon 符号秩检验。
共评估了 126 个 PET 阳性病变。总的来说,PET/CT 和 PET/MRI 在病变显著性方面没有统计学上的优势(p=0.095;CT 平均评分 2.93,MRI 平均评分 2.75)。在肺病变方面,PET/CT 的显著性明显优于 PET/MRI(p=0.016)。此外,在“淋巴结”方面,PET/CT 的显著性也明显优于 PET/MRI(p=0.033)。与 PET/MRI 相比,PET/CT 中骨病变的平均评分更高;然而,这些差异没有达到统计学意义。
总的来说,使用体线圈采集的 PET/MRI 与标准低剂量 PET/CT 的诊断准确性不完全匹配。因此,它可能仅在极少数患者中作为后备解决方案。总的来说,需要在 MR 成像部分投入更多的时间(更高的矩阵、更多的屏气、额外的表面线圈采集序列),以与标准低剂量 PET/CT 相匹配。
评估使用体线圈的 PET/MRI 与标准低剂量 PET/CT 相比是否具有诊断意义。
使用体线圈的 PET/MRI 与标准低剂量 PET/CT 的诊断准确性不完全匹配。
PET/MRI 可能仅作为患者的后备解决方案。